- Uncomplicated Gonococcal Infection
- Gonococcal Arthritis
- Gonococcal Meningitis and Endocarditis
Gonorrhea Therapeutics Market was valued at USD 1,365.3 million in 2023 and is expected to grow at an 4.6% CAGR from 2024-2030. Gonorrhea is a common sexually transmitted infection caused by the bacterium Neisseria gonorrhoeae. It is also known as ‘the clap’ or ‘drip’. Gonorrhea is the second-most commonly reported notifiable disease. The increasing incidence of Neisseria gonorrhoeae infections contributes to the demand for effective treatments. The factors that are driving this market are the growing burden of gonorrhea and growing government and private sector participation through national campaigns. Moreover, the COVID-19 pandemic also impacted the gonorrhea therapeutics market majorly. The increased number of gonorrhea cases worldwide is leading to a demand for better therapeutics, thereby driving the demand for gonorrhea therapeutics. Most cases were in the African Region and the Western Pacific Region. Thus, increasing gonorrhea cases are increasing the demand for gonorrhea therapeutics and thus driving the demand for this market. Ongoing research focuses on novel drugs and therapies.
Antimicrobial peptides, vaccines, and combination therapies offer promising avenues for improved treatment outcomes. Moreover, the growing government and private sector participation in national campaigns is also fueling the growth of the studied market. For instance, in August 2022, WHO reported that the Global Health Sector Strategy on HIV, Hepatitis, and STIs (2022-2030) has set targets to reduce the number of new cases of gonorrhea among people 15-49 years old from 82.3 million per year in 2020 to 8.23 million per year in 2030, thus reducing the annual incidence by 90% by 2030. The effective prevention and control of gonococcal infections by using prevention messages, interventions, and the right treatment plans. However, gonorrhea’s ability to develop resistance poses a significant challenge. Overcoming resistance requires innovative approaches and new therapeutic options. Moreover, financial constraints hinder the therapeutic advancements. Dual therapy (combining two drugs) enhances treatment efficacy and addresses resistance. Researchers explore synergistic approaches to combat gonorrhea. Advanced diagnostics and personalized medicine contribute to precise treatment strategies. Targeted therapies improve patient outcomes.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The COVID-19 pandemic impacted routine sexually transmitted infection services, suggesting an increase in syndromic sexually transmitted infections and missing asymptomatic cases. The pandemic also had a major impact on the gonorrhea therapeutics market. For instance, according to a research study2022, testing and treatment algorithms for sexually transmitted diseases (STDs) like gonorrhea were impacted during the pandemic due to a decrease in staffing coupled with reduced diagnostic capability and disturbances in the supply chain that led to a decrease or delay in gonorrhea diagnosis and treatment that led to an increase in gonorrhea. Thus, the COVID-19 pandemic impacted the gonorrhea therapeutics market. However, in the current scenario, with the decrease in COVID-19 cases and the resumption of healthcare services, the market is expected to witness significant growth over the forecast period. The other factors that are driving this market are the growing burden of gonorrhea and growing government and private sector participation through national campaigns. The increased number of gonorrhea cases worldwide is leading to a demand for better therapeutics, thereby driving the demand for gonorrhea therapeutics.
Gonorrhea Therapeutics Market was valued at USD 1,365.3 million in 2023 and is expected to grow at an 4.6% CAGR from 2024 to 2030.
AbbVie (Allergan, Inc.), F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, and Pfizer Inc. are some of the major players operating in the gonorrhea therapeutics market.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the gonorrhea therapeutics market.
Gonorrhea’s ability to develop resistance poses a significant challenge. Moreover, financial constraints hindering therapeutic advancements are expected to limit the growth of the gonorrhea therapeutics market.
1.Executive Summary |
2.Global Gonorrhea Therapeutics Market Introduction |
2.1.Global Gonorrhea Therapeutics Market - Taxonomy |
2.2.Global Gonorrhea Therapeutics Market - Definitions |
2.2.1.Gonococcal Infection |
2.2.2.Treatment |
2.2.3.Route of Administration |
2.2.4.End User |
2.2.5.Region |
3.Global Gonorrhea Therapeutics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Gonorrhea Therapeutics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Gonorrhea Therapeutics Market By Gonococcal Infection, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Uncomplicated Gonococcal Infection |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Gonococcal Arthritis |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Gonococcal Meningitis and Endocarditis |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
6.Global Gonorrhea Therapeutics Market By Treatment, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Monotherapy |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Dual Therapy |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Gonorrhea Therapeutics Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Oral |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Injectable |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
8.Global Gonorrhea Therapeutics Market By End User, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. Hospital Pharmacies |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Retail Pharmacies |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Online Pharmacies |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Others |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9.Global Gonorrhea Therapeutics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Gonococcal Infection Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Uncomplicated Gonococcal Infection |
10.1.2.Gonococcal Arthritis |
10.1.3.Gonococcal Meningitis and Endocarditis |
10.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Monotherapy |
10.2.2.Dual Therapy |
10.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Oral |
10.3.2.Injectable |
10.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Hospital Pharmacies |
10.4.2.Retail Pharmacies |
10.4.3.Online Pharmacies |
10.4.4.Others |
10.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Gonococcal Infection Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Uncomplicated Gonococcal Infection |
11.1.2.Gonococcal Arthritis |
11.1.3.Gonococcal Meningitis and Endocarditis |
11.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Monotherapy |
11.2.2.Dual Therapy |
11.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Oral |
11.3.2.Injectable |
11.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Hospital Pharmacies |
11.4.2.Retail Pharmacies |
11.4.3.Online Pharmacies |
11.4.4.Others |
11.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Gonococcal Infection Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Uncomplicated Gonococcal Infection |
12.1.2.Gonococcal Arthritis |
12.1.3.Gonococcal Meningitis and Endocarditis |
12.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Monotherapy |
12.2.2.Dual Therapy |
12.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Oral |
12.3.2.Injectable |
12.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Hospital Pharmacies |
12.4.2.Retail Pharmacies |
12.4.3.Online Pharmacies |
12.4.4.Others |
12.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Gonococcal Infection Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Uncomplicated Gonococcal Infection |
13.1.2.Gonococcal Arthritis |
13.1.3.Gonococcal Meningitis and Endocarditis |
13.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Monotherapy |
13.2.2.Dual Therapy |
13.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Oral |
13.3.2.Injectable |
13.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Hospital Pharmacies |
13.4.2.Retail Pharmacies |
13.4.3.Online Pharmacies |
13.4.4.Others |
13.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Gonorrhea Therapeutics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
14.1. Gonococcal Infection Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Uncomplicated Gonococcal Infection |
14.1.2.Gonococcal Arthritis |
14.1.3.Gonococcal Meningitis and Endocarditis |
14.2. Treatment Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Monotherapy |
14.2.2.Dual Therapy |
14.3. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Oral |
14.3.2.Injectable |
14.4. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Hospital Pharmacies |
14.4.2.Retail Pharmacies |
14.4.3.Online Pharmacies |
14.4.4.Others |
14.5. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.AbbVie |
15.2.2.Allergan, Inc. |
15.2.3.Hoffmann-La Roche Ltd |
15.2.4.GlaxoSmithKline plc |
15.2.5.Lupin Pharmaceuticals |
15.2.6.Pfizer Inc. |
15.2.7.Teligent, Inc. |
15.2.8.Merck & Co., Inc. |
15.2.9.Hologic, Inc. |
15.2.10.Danaher Corporation |
15.2.11.Abbott |
15.2.12.Becton Dickinson and Company |
16. Research Methodology |
17. Appendix and Abbreviations |